Company news
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news
Rhythm Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 14, 2020: Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head…
Press releases — page 5
Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International
September 13, 2020
Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results
August 2, 2020
Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations
July 26, 2020
Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer
July 19, 2020
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism
July 15, 2020
Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities
June 30, 2020
Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
June 23, 2020
Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
May 12, 2020
Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results
May 3, 2020
Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations
March 29, 2020
Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome
March 17, 2020
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
March 1, 2020
Rhythm Pharmaceuticals Announces Leadership Transition
January 5, 2020
Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
December 4, 2019
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
November 3, 2019
Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results
October 31, 2019
Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019
October 29, 2019
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 17, 2019
Rhythm Pharmaceuticals Provides Update on Research and Development Programs
September 24, 2019